Cure8 research brief
Finding reliable diagnostic biomarkers could help detect UC earlier and clarify immune mechanisms that drive disease; GPR97 is proposed here as such a marker and a possible immunomodulatory target, which may interest people following research toward better tests or therapies.
Researchers studying IBD biomarkers or immune mechanisms, clinicians interested in emerging diagnostic markers for UC, and patients following IBD research developments.
This preprint reports a bioinformatics and experimental study that identifies GPR97 (ADGRG3) as a candidate immune-related biomarker in ulcerative colitis (UC).
The authors screened public transcriptomic datasets from blood and colon tissue, used WGCNA and machine-learning steps to nominate hub genes, and validated GPR97 in independent datasets and in experimental samples from a mouse colitis model and clinical colon biopsies. They also report that sulfasalazine (SASP) treatment reduced GPR97 levels in their models.
The study presents GPR97 as consistently upregulated in UC blood and colon tissue with good diagnostic discrimination (AUCs reported >0.8 in the abstract) and links its expression to several immune cell types.
The work combines computational analysis with some experimental validation, but the source is a Research Square preprint (structured content depth: abstract) and has not completed peer review. Keep practical in mind: this is an early-stage research report suggesting GPR97 as a possible biomarker and target.
It does not establish clinical utility, approved diagnostics, or treatments based on GPR97. Further independent replication, peer review, and clinical studies would be needed before this could change patient care.
This is a preprint on Research Square (posted content) with analyses based on public datasets plus mouse and limited human biopsy validation. Preprints are not peer reviewed; results should be considered preliminary. The reported link to sulfasalazine reflects experimental intervention in the study and is not evidence to guide clinical treatment changes.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study links shared gene-expression patterns between IBD and ankylosing spondylitis and highlights STAT3 as a potential shared biomarker or therapeutic target, which could be relevant for understanding overlapping...
Researchers used genetics, microbiome, metabolism, and immune profiling together to nominate biological pathways and a four-gene signature that might help diagnose or explain ulcerative colitis. If validated later, these...
The work searches for shared blood-based gene signatures and biomarkers across HLA-B27–linked diseases (including Crohn’s disease and ulcerative colitis), which could point to common mechanisms or cross-disease...
